Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation-Reference-Cited by-同舟云学术

Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation

Published:2017-11-21 Issue:3 Volume:52 Page:216-223
ISSN:1869-3474
Container-title:Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Nucl Med Mol Imaging

Author:

Park Yun Soo,Lee Seok Mo^ORCID,Park Ji Sun,Bae Sang Kyun,Shim Hye-Kyung,Lee Won-Sik,Lee Sang-Min

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging

Link

http://link.springer.com/article/10.1007/s13139-017-0503-8/fulltext.html

Reference39 articles.

1. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the Mab Thera international trial (MInT) group. Lancet Oncol. 2011;12:1013–22.

2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

3. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-hodgkin lymphoma — results of a comprehensive meta-analysis. Cancer Treat Rev. 2007;33:338–46.

4. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma. N Engl J Med. 1995;333:1540–5.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. El papel de los parámetros metabólicos de la 18F-FDG PET/TC en el linfoma linfoblástico pediátrico;Revista Española de Medicina Nuclear e Imagen Molecular;2022-03

2. Value of baseline and end of chemotherapy 18F-FDG PET/CT in pediatric patients with Burkitt lymphoma;Leukemia & Lymphoma;2021-06-24

3. The role of 18F-FDG PET/CT metabolic parameters in pediatric lymphoblastic lymphoma;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2021-01

4. Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma;Diagnostics;2020-11-24

5. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas;Annals of Nuclear Medicine;2020-09-13